Adamis Provides Update on the Phase 2/3 Trial of Tempol in COVID-19 Positive High-Risk Subjects
The DSMB did note that no safety concerns were identified in the subjects that received Tempol.
- The DSMB did note that no safety concerns were identified in the subjects that received Tempol.
- We are obviously disappointed that the study did not meet its endpoints, said Ron Moss, MD, Chief Medical Officer of Adamis.
- I would like to thank our clinical research partners, the trial investigators and all the trial subjects for their participation.
- Tempol is in development for the treatment of patients with COVID-19 and a Phase 2/3 clinical trial has been conducted.